中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2014年
8期
20-22,38
,共4页
杨乐伟%孙玉勤%陈嘉洛%杨光伟
楊樂偉%孫玉勤%陳嘉洛%楊光偉
양악위%손옥근%진가락%양광위
白细胞介素-11%鼻咽癌%放射治疗%口腔黏膜炎%药物疗法
白細胞介素-11%鼻嚥癌%放射治療%口腔黏膜炎%藥物療法
백세포개소-11%비인암%방사치료%구강점막염%약물요법
Interleukin-11%Nasopharyngeal carcinoma%Radiation therapy%Oral mucositis%Drug therapy
目的:探讨白细胞介素-11(IL-11)雾化吸入治疗鼻咽癌同期放化疗导致口腔黏膜炎的临床疗效,为鼻咽癌同期放化疗导致口腔黏膜炎的治疗提供新方法。方法选取2010年4月~2013年6月间于我院肿瘤科住院治疗的初诊为鼻咽癌的患者84例,于放疗后2周即药物雾化吸入前,及放疗第3~7周观察口腔黏膜反应变化情况;于放疗结束后1周,观察口腔黏膜反应愈合情况,对比分析IL-11雾化吸入对鼻咽癌同期放化疗导致口腔黏膜炎的治疗效果。结果两组患者放疗后第2周均出现口腔黏膜反应,但观察组患者的口腔黏膜反应分级与对照组相比无显著变化,但随着放射治疗的持续以及放射剂量的增加,观察组患者的口腔黏膜反应分级以Ⅰ~Ⅱ度黏膜反应为主,而对照组患者的口腔黏膜反应分级以Ⅱ~Ⅲ度黏膜反应为主,两组患者组间比较发现,观察组患者的口腔黏膜反应程度较对照组显著增加(P<0.05);放疗结束1周后,观察组对于口腔黏膜炎治疗的总有效率为90.5%,与对照组相比显著升高(x2=27.064,P=0.000)。结论 IL-11雾化吸入能够有效减轻鼻咽癌同期放化疗导致口腔黏膜反应的程度,对于口腔黏膜炎的治疗具有促进作用。
目的:探討白細胞介素-11(IL-11)霧化吸入治療鼻嚥癌同期放化療導緻口腔黏膜炎的臨床療效,為鼻嚥癌同期放化療導緻口腔黏膜炎的治療提供新方法。方法選取2010年4月~2013年6月間于我院腫瘤科住院治療的初診為鼻嚥癌的患者84例,于放療後2週即藥物霧化吸入前,及放療第3~7週觀察口腔黏膜反應變化情況;于放療結束後1週,觀察口腔黏膜反應愈閤情況,對比分析IL-11霧化吸入對鼻嚥癌同期放化療導緻口腔黏膜炎的治療效果。結果兩組患者放療後第2週均齣現口腔黏膜反應,但觀察組患者的口腔黏膜反應分級與對照組相比無顯著變化,但隨著放射治療的持續以及放射劑量的增加,觀察組患者的口腔黏膜反應分級以Ⅰ~Ⅱ度黏膜反應為主,而對照組患者的口腔黏膜反應分級以Ⅱ~Ⅲ度黏膜反應為主,兩組患者組間比較髮現,觀察組患者的口腔黏膜反應程度較對照組顯著增加(P<0.05);放療結束1週後,觀察組對于口腔黏膜炎治療的總有效率為90.5%,與對照組相比顯著升高(x2=27.064,P=0.000)。結論 IL-11霧化吸入能夠有效減輕鼻嚥癌同期放化療導緻口腔黏膜反應的程度,對于口腔黏膜炎的治療具有促進作用。
목적:탐토백세포개소-11(IL-11)무화흡입치료비인암동기방화료도치구강점막염적림상료효,위비인암동기방화료도치구강점막염적치료제공신방법。방법선취2010년4월~2013년6월간우아원종류과주원치료적초진위비인암적환자84례,우방료후2주즉약물무화흡입전,급방료제3~7주관찰구강점막반응변화정황;우방료결속후1주,관찰구강점막반응유합정황,대비분석IL-11무화흡입대비인암동기방화료도치구강점막염적치료효과。결과량조환자방료후제2주균출현구강점막반응,단관찰조환자적구강점막반응분급여대조조상비무현저변화,단수착방사치료적지속이급방사제량적증가,관찰조환자적구강점막반응분급이Ⅰ~Ⅱ도점막반응위주,이대조조환자적구강점막반응분급이Ⅱ~Ⅲ도점막반응위주,량조환자조간비교발현,관찰조환자적구강점막반응정도교대조조현저증가(P<0.05);방료결속1주후,관찰조대우구강점막염치료적총유효솔위90.5%,여대조조상비현저승고(x2=27.064,P=0.000)。결론 IL-11무화흡입능구유효감경비인암동기방화료도치구강점막반응적정도,대우구강점막염적치료구유촉진작용。
Objective To investigate the clinical efficacy of interleukin-11(IL-11) inhalation treatment of oral mucositis caused by concurrent chemo-radiotherapy of nasopharyngeal carcinoma and to provide a new method for the treatment of oral mucositis caused by concurrent chemo-radiotherapy of nasopharyngeal carcinoma. Methods 84 patients were selected in the oncology of our hospital during April 2010 to June 2013, which were diagnosed with newly nasopharyngeal cancer. The changes of oral mucositis were observed before the drug inhalation and 3-7 weeks after radiotherapy, and the healing of oral mucositis were also observed one week after the end of radiotherapy. And then the clinical efficacies of interleukin-11(IL-11) inhalation treatment of oral mucositis caused by concurrent chemo-radiotherapy of nasopharyngeal carcinoma were analyzed comparatively. Results In the first two weeks, the patients of both two groups existed oral mucositis after radiotherapy, but compared with the control group, oral mucositis classification in the observation group had no change significantly, but with the continued increase in radiation dose and radiation therapy, the degree of the patients in the observation group were mainly grade Ⅰ - Ⅱdegree, and those in the control group were mainly Ⅱ - Ⅲ degree. Between two groups of patients found the oral mucosa of patients in the observation group compared with the extent of reaction the control group was significantly increased(P < 0.05); 1 week after the end of radiotherapy, the effective rate was 90.5% in the observation group to the total oral mucositis treatment, compared with the control group was significantly higher(x2=27.064,P=0.000). Conclusion IL-11 inhalation can effectively reduce the degree of oral mucositis caused by nasopharyngeal concurrent chemo-radiotherapy, and has a facilitating role for the treatment of oral mucositis.